nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—ABCB1—ovarian cancer	0.332	1	CbGaD
Citalopram—ABCB1—Topotecan—ovarian cancer	0.0481	0.168	CbGbCtD
Citalopram—ABCB1—Vinorelbine—ovarian cancer	0.0339	0.118	CbGbCtD
Citalopram—CYP2D6—Vinorelbine—ovarian cancer	0.032	0.112	CbGbCtD
Citalopram—CYP3A4—Topotecan—ovarian cancer	0.0288	0.101	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—ovarian cancer	0.0251	0.0874	CbGbCtD
Citalopram—ABCB1—Paclitaxel—ovarian cancer	0.0238	0.0832	CbGbCtD
Citalopram—CYP3A4—Vinorelbine—ovarian cancer	0.0203	0.0709	CbGbCtD
Citalopram—ABCB1—Docetaxel—ovarian cancer	0.0172	0.0601	CbGbCtD
Citalopram—CYP3A4—Paclitaxel—ovarian cancer	0.0143	0.0498	CbGbCtD
Citalopram—ABCB1—Doxorubicin—ovarian cancer	0.0128	0.0448	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—ovarian cancer	0.0121	0.0422	CbGbCtD
Citalopram—CYP3A4—Docetaxel—ovarian cancer	0.0103	0.036	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—ovarian cancer	0.0077	0.0269	CbGbCtD
Citalopram—Oedema—Docetaxel—ovarian cancer	0.000103	0.000296	CcSEcCtD
Citalopram—Weight increased—Doxorubicin—ovarian cancer	0.000102	0.000295	CcSEcCtD
Citalopram—Epistaxis—Epirubicin—ovarian cancer	0.000102	0.000295	CcSEcCtD
Citalopram—Infection—Docetaxel—ovarian cancer	0.000102	0.000294	CcSEcCtD
Citalopram—Weight decreased—Doxorubicin—ovarian cancer	0.000102	0.000294	CcSEcCtD
Citalopram—Sinusitis—Epirubicin—ovarian cancer	0.000102	0.000293	CcSEcCtD
Citalopram—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000101	0.000293	CcSEcCtD
Citalopram—Agranulocytosis—Epirubicin—ovarian cancer	0.000101	0.000292	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—ovarian cancer	0.000101	0.000291	CcSEcCtD
Citalopram—Shock—Docetaxel—ovarian cancer	0.000101	0.000291	CcSEcCtD
Citalopram—Nervous system disorder—Docetaxel—ovarian cancer	0.000101	0.00029	CcSEcCtD
Citalopram—Thrombocytopenia—Docetaxel—ovarian cancer	0.0001	0.00029	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—ovarian cancer	0.0001	0.000289	CcSEcCtD
Citalopram—Infestation—Doxorubicin—ovarian cancer	0.0001	0.000289	CcSEcCtD
Citalopram—Tachycardia—Docetaxel—ovarian cancer	0.0001	0.000289	CcSEcCtD
Citalopram—Feeling abnormal—Paclitaxel—ovarian cancer	9.97e-05	0.000288	CcSEcCtD
Citalopram—Skin disorder—Docetaxel—ovarian cancer	9.96e-05	0.000287	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	9.94e-05	0.000287	CcSEcCtD
Citalopram—Bradycardia—Epirubicin—ovarian cancer	9.91e-05	0.000286	CcSEcCtD
Citalopram—Gastrointestinal pain—Paclitaxel—ovarian cancer	9.89e-05	0.000285	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—ovarian cancer	9.83e-05	0.000284	CcSEcCtD
Citalopram—Haemoglobin—Epirubicin—ovarian cancer	9.78e-05	0.000282	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—ovarian cancer	9.78e-05	0.000282	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—ovarian cancer	9.78e-05	0.000282	CcSEcCtD
Citalopram—Anorexia—Docetaxel—ovarian cancer	9.77e-05	0.000282	CcSEcCtD
Citalopram—Rhinitis—Epirubicin—ovarian cancer	9.76e-05	0.000281	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—ovarian cancer	9.75e-05	0.000281	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—ovarian cancer	9.75e-05	0.000281	CcSEcCtD
Citalopram—Haemorrhage—Epirubicin—ovarian cancer	9.73e-05	0.000281	CcSEcCtD
Citalopram—Hepatitis—Epirubicin—ovarian cancer	9.73e-05	0.000281	CcSEcCtD
Citalopram—Hypoaesthesia—Epirubicin—ovarian cancer	9.68e-05	0.000279	CcSEcCtD
Citalopram—Pharyngitis—Epirubicin—ovarian cancer	9.66e-05	0.000279	CcSEcCtD
Citalopram—Sweating—Doxorubicin—ovarian cancer	9.62e-05	0.000277	CcSEcCtD
Citalopram—Urinary tract disorder—Epirubicin—ovarian cancer	9.61e-05	0.000277	CcSEcCtD
Citalopram—Urticaria—Paclitaxel—ovarian cancer	9.61e-05	0.000277	CcSEcCtD
Citalopram—Oedema peripheral—Epirubicin—ovarian cancer	9.59e-05	0.000277	CcSEcCtD
Citalopram—Hypotension—Docetaxel—ovarian cancer	9.58e-05	0.000276	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—ovarian cancer	9.56e-05	0.000276	CcSEcCtD
Citalopram—Connective tissue disorder—Epirubicin—ovarian cancer	9.56e-05	0.000276	CcSEcCtD
Citalopram—Body temperature increased—Paclitaxel—ovarian cancer	9.56e-05	0.000276	CcSEcCtD
Citalopram—Abdominal pain—Paclitaxel—ovarian cancer	9.56e-05	0.000276	CcSEcCtD
Citalopram—Urethral disorder—Epirubicin—ovarian cancer	9.54e-05	0.000275	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—ovarian cancer	9.49e-05	0.000274	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—ovarian cancer	9.46e-05	0.000273	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—ovarian cancer	9.41e-05	0.000272	CcSEcCtD
Citalopram—Visual impairment—Epirubicin—ovarian cancer	9.38e-05	0.000271	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—ovarian cancer	9.36e-05	0.00027	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.34e-05	0.000269	CcSEcCtD
Citalopram—Insomnia—Docetaxel—ovarian cancer	9.27e-05	0.000268	CcSEcCtD
Citalopram—Paraesthesia—Docetaxel—ovarian cancer	9.2e-05	0.000266	CcSEcCtD
Citalopram—Erythema multiforme—Epirubicin—ovarian cancer	9.2e-05	0.000265	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—ovarian cancer	9.17e-05	0.000264	CcSEcCtD
Citalopram—Dyspnoea—Docetaxel—ovarian cancer	9.14e-05	0.000264	CcSEcCtD
Citalopram—Somnolence—Docetaxel—ovarian cancer	9.11e-05	0.000263	CcSEcCtD
Citalopram—Eye disorder—Epirubicin—ovarian cancer	9.09e-05	0.000262	CcSEcCtD
Citalopram—Tinnitus—Epirubicin—ovarian cancer	9.07e-05	0.000262	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—ovarian cancer	9.05e-05	0.000261	CcSEcCtD
Citalopram—Flushing—Epirubicin—ovarian cancer	9.03e-05	0.000261	CcSEcCtD
Citalopram—Cardiac disorder—Epirubicin—ovarian cancer	9.03e-05	0.000261	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—ovarian cancer	9.03e-05	0.00026	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—ovarian cancer	9.02e-05	0.00026	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—ovarian cancer	9e-05	0.00026	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—ovarian cancer	9e-05	0.00026	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—ovarian cancer	8.96e-05	0.000259	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—ovarian cancer	8.94e-05	0.000258	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—ovarian cancer	8.91e-05	0.000257	CcSEcCtD
Citalopram—Hypersensitivity—Paclitaxel—ovarian cancer	8.91e-05	0.000257	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—ovarian cancer	8.89e-05	0.000257	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—ovarian cancer	8.87e-05	0.000256	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.85e-05	0.000255	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—ovarian cancer	8.85e-05	0.000255	CcSEcCtD
Citalopram—Fatigue—Docetaxel—ovarian cancer	8.84e-05	0.000255	CcSEcCtD
Citalopram—Angiopathy—Epirubicin—ovarian cancer	8.83e-05	0.000255	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—ovarian cancer	8.83e-05	0.000255	CcSEcCtD
Citalopram—Immune system disorder—Epirubicin—ovarian cancer	8.79e-05	0.000254	CcSEcCtD
Citalopram—Mediastinal disorder—Epirubicin—ovarian cancer	8.77e-05	0.000253	CcSEcCtD
Citalopram—Pain—Docetaxel—ovarian cancer	8.77e-05	0.000253	CcSEcCtD
Citalopram—Constipation—Docetaxel—ovarian cancer	8.77e-05	0.000253	CcSEcCtD
Citalopram—Chills—Epirubicin—ovarian cancer	8.73e-05	0.000252	CcSEcCtD
Citalopram—Arrhythmia—Epirubicin—ovarian cancer	8.69e-05	0.000251	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—ovarian cancer	8.68e-05	0.00025	CcSEcCtD
Citalopram—Asthenia—Paclitaxel—ovarian cancer	8.68e-05	0.00025	CcSEcCtD
Citalopram—Alopecia—Epirubicin—ovarian cancer	8.6e-05	0.000248	CcSEcCtD
Citalopram—Pruritus—Paclitaxel—ovarian cancer	8.56e-05	0.000247	CcSEcCtD
Citalopram—Mental disorder—Epirubicin—ovarian cancer	8.53e-05	0.000246	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—ovarian cancer	8.51e-05	0.000246	CcSEcCtD
Citalopram—Erythema—Epirubicin—ovarian cancer	8.47e-05	0.000244	CcSEcCtD
Citalopram—Malnutrition—Epirubicin—ovarian cancer	8.47e-05	0.000244	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—ovarian cancer	8.45e-05	0.000244	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—ovarian cancer	8.42e-05	0.000243	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—ovarian cancer	8.4e-05	0.000242	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—ovarian cancer	8.38e-05	0.000242	CcSEcCtD
Citalopram—Flushing—Doxorubicin—ovarian cancer	8.36e-05	0.000241	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—ovarian cancer	8.36e-05	0.000241	CcSEcCtD
Citalopram—Flatulence—Epirubicin—ovarian cancer	8.35e-05	0.000241	CcSEcCtD
Citalopram—Tension—Epirubicin—ovarian cancer	8.31e-05	0.00024	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—ovarian cancer	8.3e-05	0.000239	CcSEcCtD
Citalopram—Diarrhoea—Paclitaxel—ovarian cancer	8.27e-05	0.000239	CcSEcCtD
Citalopram—Nervousness—Epirubicin—ovarian cancer	8.23e-05	0.000237	CcSEcCtD
Citalopram—Back pain—Epirubicin—ovarian cancer	8.19e-05	0.000236	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—ovarian cancer	8.17e-05	0.000236	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—ovarian cancer	8.14e-05	0.000235	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—ovarian cancer	8.13e-05	0.000235	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—ovarian cancer	8.12e-05	0.000234	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—ovarian cancer	8.1e-05	0.000234	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—ovarian cancer	8.1e-05	0.000234	CcSEcCtD
Citalopram—Chills—Doxorubicin—ovarian cancer	8.08e-05	0.000233	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—ovarian cancer	8.04e-05	0.000232	CcSEcCtD
Citalopram—Dizziness—Paclitaxel—ovarian cancer	8e-05	0.000231	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—ovarian cancer	7.98e-05	0.00023	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—ovarian cancer	7.96e-05	0.00023	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—ovarian cancer	7.89e-05	0.000228	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—ovarian cancer	7.86e-05	0.000227	CcSEcCtD
Citalopram—Erythema—Doxorubicin—ovarian cancer	7.84e-05	0.000226	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—ovarian cancer	7.84e-05	0.000226	CcSEcCtD
Citalopram—Anaemia—Epirubicin—ovarian cancer	7.83e-05	0.000226	CcSEcCtD
Citalopram—Agitation—Epirubicin—ovarian cancer	7.79e-05	0.000225	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—ovarian cancer	7.72e-05	0.000223	CcSEcCtD
Citalopram—Tension—Doxorubicin—ovarian cancer	7.69e-05	0.000222	CcSEcCtD
Citalopram—Vomiting—Paclitaxel—ovarian cancer	7.69e-05	0.000222	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—ovarian cancer	7.68e-05	0.000221	CcSEcCtD
Citalopram—Malaise—Epirubicin—ovarian cancer	7.64e-05	0.00022	CcSEcCtD
Citalopram—Rash—Paclitaxel—ovarian cancer	7.63e-05	0.00022	CcSEcCtD
Citalopram—Dermatitis—Paclitaxel—ovarian cancer	7.62e-05	0.00022	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—ovarian cancer	7.61e-05	0.00022	CcSEcCtD
Citalopram—Vertigo—Epirubicin—ovarian cancer	7.61e-05	0.00022	CcSEcCtD
Citalopram—Syncope—Epirubicin—ovarian cancer	7.6e-05	0.000219	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—ovarian cancer	7.58e-05	0.000219	CcSEcCtD
Citalopram—Back pain—Doxorubicin—ovarian cancer	7.58e-05	0.000219	CcSEcCtD
Citalopram—Headache—Paclitaxel—ovarian cancer	7.58e-05	0.000219	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—ovarian cancer	7.55e-05	0.000218	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—ovarian cancer	7.54e-05	0.000217	CcSEcCtD
Citalopram—Palpitations—Epirubicin—ovarian cancer	7.49e-05	0.000216	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—ovarian cancer	7.45e-05	0.000215	CcSEcCtD
Citalopram—Cough—Epirubicin—ovarian cancer	7.39e-05	0.000213	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—ovarian cancer	7.39e-05	0.000213	CcSEcCtD
Citalopram—Asthenia—Docetaxel—ovarian cancer	7.35e-05	0.000212	CcSEcCtD
Citalopram—Convulsion—Epirubicin—ovarian cancer	7.34e-05	0.000212	CcSEcCtD
Citalopram—Hypertension—Epirubicin—ovarian cancer	7.31e-05	0.000211	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—ovarian cancer	7.27e-05	0.00021	CcSEcCtD
Citalopram—Pruritus—Docetaxel—ovarian cancer	7.25e-05	0.000209	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—ovarian cancer	7.25e-05	0.000209	CcSEcCtD
Citalopram—Chest pain—Epirubicin—ovarian cancer	7.21e-05	0.000208	CcSEcCtD
Citalopram—Myalgia—Epirubicin—ovarian cancer	7.21e-05	0.000208	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—ovarian cancer	7.21e-05	0.000208	CcSEcCtD
Citalopram—Agitation—Doxorubicin—ovarian cancer	7.2e-05	0.000208	CcSEcCtD
Citalopram—Anxiety—Epirubicin—ovarian cancer	7.19e-05	0.000207	CcSEcCtD
Citalopram—Nausea—Paclitaxel—ovarian cancer	7.18e-05	0.000207	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.16e-05	0.000207	CcSEcCtD
Citalopram—Discomfort—Epirubicin—ovarian cancer	7.13e-05	0.000206	CcSEcCtD
Citalopram—Malaise—Doxorubicin—ovarian cancer	7.07e-05	0.000204	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—ovarian cancer	7.05e-05	0.000204	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—ovarian cancer	7.04e-05	0.000203	CcSEcCtD
Citalopram—Syncope—Doxorubicin—ovarian cancer	7.03e-05	0.000203	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—ovarian cancer	7.02e-05	0.000202	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—ovarian cancer	7.01e-05	0.000202	CcSEcCtD
Citalopram—Confusional state—Epirubicin—ovarian cancer	6.97e-05	0.000201	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—ovarian cancer	6.93e-05	0.0002	CcSEcCtD
Citalopram—Oedema—Epirubicin—ovarian cancer	6.91e-05	0.000199	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—ovarian cancer	6.91e-05	0.000199	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—ovarian cancer	6.89e-05	0.000199	CcSEcCtD
Citalopram—Infection—Epirubicin—ovarian cancer	6.87e-05	0.000198	CcSEcCtD
Citalopram—Cough—Doxorubicin—ovarian cancer	6.84e-05	0.000197	CcSEcCtD
Citalopram—Shock—Epirubicin—ovarian cancer	6.8e-05	0.000196	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—ovarian cancer	6.79e-05	0.000196	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—ovarian cancer	6.78e-05	0.000196	CcSEcCtD
Citalopram—Dizziness—Docetaxel—ovarian cancer	6.78e-05	0.000196	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—ovarian cancer	6.77e-05	0.000195	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—ovarian cancer	6.77e-05	0.000195	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—ovarian cancer	6.75e-05	0.000195	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—ovarian cancer	6.72e-05	0.000194	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—ovarian cancer	6.68e-05	0.000193	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—ovarian cancer	6.67e-05	0.000193	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—ovarian cancer	6.67e-05	0.000193	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—ovarian cancer	6.67e-05	0.000193	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—ovarian cancer	6.65e-05	0.000192	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.63e-05	0.000191	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—ovarian cancer	6.59e-05	0.00019	CcSEcCtD
Citalopram—Anorexia—Epirubicin—ovarian cancer	6.59e-05	0.00019	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—ovarian cancer	6.53e-05	0.000188	CcSEcCtD
Citalopram—Vomiting—Docetaxel—ovarian cancer	6.52e-05	0.000188	CcSEcCtD
Citalopram—Rash—Docetaxel—ovarian cancer	6.46e-05	0.000186	CcSEcCtD
Citalopram—Hypotension—Epirubicin—ovarian cancer	6.46e-05	0.000186	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—ovarian cancer	6.46e-05	0.000186	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—ovarian cancer	6.45e-05	0.000186	CcSEcCtD
Citalopram—Headache—Docetaxel—ovarian cancer	6.42e-05	0.000185	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—ovarian cancer	6.4e-05	0.000185	CcSEcCtD
Citalopram—Oedema—Doxorubicin—ovarian cancer	6.4e-05	0.000185	CcSEcCtD
Citalopram—Infection—Doxorubicin—ovarian cancer	6.36e-05	0.000183	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.3e-05	0.000182	CcSEcCtD
Citalopram—Shock—Doxorubicin—ovarian cancer	6.29e-05	0.000182	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—ovarian cancer	6.27e-05	0.000181	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—ovarian cancer	6.26e-05	0.000181	CcSEcCtD
Citalopram—Insomnia—Epirubicin—ovarian cancer	6.25e-05	0.00018	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—ovarian cancer	6.24e-05	0.00018	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—ovarian cancer	6.21e-05	0.000179	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—ovarian cancer	6.21e-05	0.000179	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—ovarian cancer	6.18e-05	0.000178	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—ovarian cancer	6.16e-05	0.000178	CcSEcCtD
Citalopram—Somnolence—Epirubicin—ovarian cancer	6.15e-05	0.000177	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—ovarian cancer	6.1e-05	0.000176	CcSEcCtD
Citalopram—Nausea—Docetaxel—ovarian cancer	6.09e-05	0.000176	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—ovarian cancer	6.09e-05	0.000176	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—ovarian cancer	6.01e-05	0.000173	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—ovarian cancer	5.98e-05	0.000172	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.97e-05	0.000172	CcSEcCtD
Citalopram—Fatigue—Epirubicin—ovarian cancer	5.96e-05	0.000172	CcSEcCtD
Citalopram—Constipation—Epirubicin—ovarian cancer	5.91e-05	0.000171	CcSEcCtD
Citalopram—Pain—Epirubicin—ovarian cancer	5.91e-05	0.000171	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.83e-05	0.000168	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—ovarian cancer	5.79e-05	0.000167	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—ovarian cancer	5.74e-05	0.000166	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—ovarian cancer	5.7e-05	0.000165	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—ovarian cancer	5.7e-05	0.000164	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—ovarian cancer	5.69e-05	0.000164	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—ovarian cancer	5.65e-05	0.000163	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—ovarian cancer	5.63e-05	0.000162	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—ovarian cancer	5.56e-05	0.00016	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.52e-05	0.000159	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—ovarian cancer	5.52e-05	0.000159	CcSEcCtD
Citalopram—Urticaria—Epirubicin—ovarian cancer	5.49e-05	0.000158	CcSEcCtD
Citalopram—Constipation—Doxorubicin—ovarian cancer	5.47e-05	0.000158	CcSEcCtD
Citalopram—Pain—Doxorubicin—ovarian cancer	5.47e-05	0.000158	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—ovarian cancer	5.47e-05	0.000158	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—ovarian cancer	5.47e-05	0.000158	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—ovarian cancer	5.27e-05	0.000152	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.23e-05	0.000151	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—ovarian cancer	5.09e-05	0.000147	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—ovarian cancer	5.08e-05	0.000147	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—ovarian cancer	5.06e-05	0.000146	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—ovarian cancer	5.06e-05	0.000146	CcSEcCtD
Citalopram—Asthenia—Epirubicin—ovarian cancer	4.96e-05	0.000143	CcSEcCtD
Citalopram—Pruritus—Epirubicin—ovarian cancer	4.89e-05	0.000141	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—ovarian cancer	4.73e-05	0.000136	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—ovarian cancer	4.71e-05	0.000136	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—ovarian cancer	4.59e-05	0.000132	CcSEcCtD
Citalopram—Dizziness—Epirubicin—ovarian cancer	4.57e-05	0.000132	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—ovarian cancer	4.53e-05	0.000131	CcSEcCtD
Citalopram—Vomiting—Epirubicin—ovarian cancer	4.4e-05	0.000127	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—ovarian cancer	4.38e-05	0.000126	CcSEcCtD
Citalopram—Rash—Epirubicin—ovarian cancer	4.36e-05	0.000126	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—ovarian cancer	4.36e-05	0.000126	CcSEcCtD
Citalopram—Headache—Epirubicin—ovarian cancer	4.33e-05	0.000125	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—ovarian cancer	4.23e-05	0.000122	CcSEcCtD
Citalopram—Nausea—Epirubicin—ovarian cancer	4.11e-05	0.000118	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—ovarian cancer	4.07e-05	0.000117	CcSEcCtD
Citalopram—Rash—Doxorubicin—ovarian cancer	4.03e-05	0.000116	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—ovarian cancer	4.03e-05	0.000116	CcSEcCtD
Citalopram—Headache—Doxorubicin—ovarian cancer	4.01e-05	0.000116	CcSEcCtD
Citalopram—Nausea—Doxorubicin—ovarian cancer	3.8e-05	0.00011	CcSEcCtD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—ovarian cancer	7.73e-06	0.000218	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—ovarian cancer	7.61e-06	0.000215	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ESR1—ovarian cancer	7.59e-06	0.000214	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	7.47e-06	0.000211	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1B1—ovarian cancer	7.45e-06	0.00021	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL2—ovarian cancer	7.41e-06	0.000209	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.39e-06	0.000208	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL2—ovarian cancer	7.39e-06	0.000208	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TERT—ovarian cancer	7.38e-06	0.000208	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TERT—ovarian cancer	7.36e-06	0.000208	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—ovarian cancer	7.27e-06	0.000205	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TERT—ovarian cancer	7.25e-06	0.000204	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	7.18e-06	0.000203	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	7.18e-06	0.000203	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APC—ovarian cancer	7.18e-06	0.000203	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	7.18e-06	0.000203	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.14e-06	0.000202	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPP2R1A—ovarian cancer	7.01e-06	0.000198	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CAV1—ovarian cancer	6.98e-06	0.000197	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—FASN—ovarian cancer	6.93e-06	0.000195	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	6.88e-06	0.000194	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CAV1—ovarian cancer	6.84e-06	0.000193	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CAV1—ovarian cancer	6.83e-06	0.000193	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC5A5—ovarian cancer	6.81e-06	0.000192	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CAV1—ovarian cancer	6.81e-06	0.000192	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CAV1—ovarian cancer	6.7e-06	0.000189	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ABCB1—ovarian cancer	6.67e-06	0.000188	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	6.6e-06	0.000186	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ESR1—ovarian cancer	6.58e-06	0.000186	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC2A1—ovarian cancer	6.58e-06	0.000186	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ESR1—ovarian cancer	6.56e-06	0.000185	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—YAP1—ovarian cancer	6.56e-06	0.000185	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TYMS—ovarian cancer	6.55e-06	0.000185	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	6.54e-06	0.000185	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	6.54e-06	0.000185	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6ST—ovarian cancer	6.47e-06	0.000183	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ESR1—ovarian cancer	6.46e-06	0.000182	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6ST—ovarian cancer	6.45e-06	0.000182	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.44e-06	0.000182	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TYMS—ovarian cancer	6.39e-06	0.00018	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CG—ovarian cancer	6.36e-06	0.000179	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6ST—ovarian cancer	6.35e-06	0.000179	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	6.31e-06	0.000178	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1B1—ovarian cancer	6.31e-06	0.000178	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	6.25e-06	0.000176	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CG—ovarian cancer	6.23e-06	0.000176	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CG—ovarian cancer	6.22e-06	0.000175	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APC—ovarian cancer	6.22e-06	0.000175	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—NRAS—ovarian cancer	6.22e-06	0.000175	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—ovarian cancer	6.2e-06	0.000175	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APC—ovarian cancer	6.2e-06	0.000175	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—NRAS—ovarian cancer	6.2e-06	0.000175	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	6.18e-06	0.000174	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ABCB1—ovarian cancer	6.13e-06	0.000173	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	6.1e-06	0.000172	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APC—ovarian cancer	6.1e-06	0.000172	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	6.1e-06	0.000172	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TYMS—ovarian cancer	6.02e-06	0.00017	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK3—ovarian cancer	5.96e-06	0.000168	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—ovarian cancer	5.94e-06	0.000168	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	5.85e-06	0.000165	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	5.68e-06	0.00016	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK1—ovarian cancer	5.67e-06	0.00016	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—ovarian cancer	5.67e-06	0.00016	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK1—ovarian cancer	5.65e-06	0.000159	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—ovarian cancer	5.65e-06	0.000159	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	5.59e-06	0.000158	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—ovarian cancer	5.59e-06	0.000158	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	5.57e-06	0.000157	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.57e-06	0.000157	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	5.56e-06	0.000157	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	5.56e-06	0.000157	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MTOR—ovarian cancer	5.5e-06	0.000155	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	5.5e-06	0.000155	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—ovarian cancer	5.48e-06	0.000154	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—ovarian cancer	5.47e-06	0.000154	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—ovarian cancer	5.45e-06	0.000154	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.42e-06	0.000153	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.4e-06	0.000152	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	5.37e-06	0.000151	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—ovarian cancer	5.35e-06	0.000151	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—FASN—ovarian cancer	5.35e-06	0.000151	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—ovarian cancer	5.34e-06	0.000151	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	5.32e-06	0.00015	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	5.29e-06	0.000149	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAV1—ovarian cancer	5.28e-06	0.000149	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.26e-06	0.000148	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	5.25e-06	0.000148	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	5.25e-06	0.000148	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—ovarian cancer	5.19e-06	0.000147	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	5.16e-06	0.000146	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAV1—ovarian cancer	5.15e-06	0.000145	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	5.11e-06	0.000144	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—ovarian cancer	5.1e-06	0.000144	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.08e-06	0.000143	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—ovarian cancer	5.06e-06	0.000143	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—ovarian cancer	5.05e-06	0.000143	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.04e-06	0.000142	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—ovarian cancer	5.03e-06	0.000142	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—ovarian cancer	4.93e-06	0.000139	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—ovarian cancer	4.92e-06	0.000139	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	4.9e-06	0.000138	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	4.88e-06	0.000138	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—ovarian cancer	4.87e-06	0.000137	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.87e-06	0.000137	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAV1—ovarian cancer	4.85e-06	0.000137	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—ovarian cancer	4.83e-06	0.000136	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	4.83e-06	0.000136	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	4.81e-06	0.000136	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—ovarian cancer	4.81e-06	0.000136	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—ovarian cancer	4.78e-06	0.000135	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—ovarian cancer	4.77e-06	0.000135	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—ovarian cancer	4.77e-06	0.000134	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	4.77e-06	0.000134	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—ovarian cancer	4.75e-06	0.000134	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—ovarian cancer	4.75e-06	0.000134	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	4.75e-06	0.000134	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	4.74e-06	0.000134	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.69e-06	0.000132	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	4.68e-06	0.000132	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	4.68e-06	0.000132	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	4.64e-06	0.000131	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—ovarian cancer	4.58e-06	0.000129	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	4.57e-06	0.000129	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—ovarian cancer	4.55e-06	0.000128	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	4.54e-06	0.000128	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	4.5e-06	0.000127	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	4.47e-06	0.000126	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	4.47e-06	0.000126	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	4.46e-06	0.000126	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	4.43e-06	0.000125	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—ovarian cancer	4.42e-06	0.000125	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	4.41e-06	0.000124	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	4.39e-06	0.000124	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—ovarian cancer	4.38e-06	0.000124	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—ovarian cancer	4.38e-06	0.000123	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—ovarian cancer	4.37e-06	0.000123	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—ovarian cancer	4.36e-06	0.000123	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—ovarian cancer	4.36e-06	0.000123	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	4.34e-06	0.000122	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—ovarian cancer	4.34e-06	0.000122	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.32e-06	0.000122	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	4.3e-06	0.000121	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—ovarian cancer	4.3e-06	0.000121	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	4.29e-06	0.000121	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	4.27e-06	0.000121	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—ovarian cancer	4.27e-06	0.00012	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—ovarian cancer	4.25e-06	0.00012	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—ovarian cancer	4.25e-06	0.00012	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—ovarian cancer	4.24e-06	0.00012	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	4.23e-06	0.000119	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—ovarian cancer	4.22e-06	0.000119	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	4.21e-06	0.000119	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—ovarian cancer	4.21e-06	0.000119	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	4.19e-06	0.000118	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	4.15e-06	0.000117	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—ovarian cancer	4.14e-06	0.000117	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—ovarian cancer	4.13e-06	0.000116	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—ovarian cancer	4.12e-06	0.000116	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.12e-06	0.000116	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—ovarian cancer	4.12e-06	0.000116	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAV1—ovarian cancer	4.11e-06	0.000116	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—ovarian cancer	4.11e-06	0.000116	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	4.07e-06	0.000115	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	4.06e-06	0.000115	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	4.04e-06	0.000114	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—ovarian cancer	4.02e-06	0.000113	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.01e-06	0.000113	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	4.01e-06	0.000113	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—ovarian cancer	3.95e-06	0.000111	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	3.94e-06	0.000111	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—ovarian cancer	3.94e-06	0.000111	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.93e-06	0.000111	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.89e-06	0.00011	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	3.86e-06	0.000109	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—ovarian cancer	3.86e-06	0.000109	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.74e-06	0.000106	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—ovarian cancer	3.72e-06	0.000105	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	3.71e-06	0.000105	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—ovarian cancer	3.68e-06	0.000104	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.68e-06	0.000104	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—ovarian cancer	3.67e-06	0.000104	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—ovarian cancer	3.67e-06	0.000104	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—ovarian cancer	3.66e-06	0.000103	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	3.65e-06	0.000103	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—ovarian cancer	3.65e-06	0.000103	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	3.61e-06	0.000102	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	3.61e-06	0.000102	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.59e-06	0.000101	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—ovarian cancer	3.52e-06	9.93e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	3.51e-06	9.9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	3.45e-06	9.74e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—ovarian cancer	3.42e-06	9.66e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—ovarian cancer	3.41e-06	9.62e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—ovarian cancer	3.39e-06	9.55e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—ovarian cancer	3.36e-06	9.47e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	3.35e-06	9.46e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK1—ovarian cancer	3.35e-06	9.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—ovarian cancer	3.35e-06	9.44e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	3.34e-06	9.42e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—ovarian cancer	3.34e-06	9.41e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.29e-06	9.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	3.29e-06	9.27e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	3.29e-06	9.27e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—ovarian cancer	3.24e-06	9.15e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—ovarian cancer	3.18e-06	8.98e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAV1—ovarian cancer	3.17e-06	8.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—ovarian cancer	3.16e-06	8.92e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—ovarian cancer	3.15e-06	8.89e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—ovarian cancer	3.11e-06	8.76e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	3.1e-06	8.75e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—ovarian cancer	3.1e-06	8.75e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—ovarian cancer	2.97e-06	8.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—ovarian cancer	2.97e-06	8.38e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—ovarian cancer	2.93e-06	8.26e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—ovarian cancer	2.91e-06	8.21e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	2.91e-06	8.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	2.9e-06	8.17e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.89e-06	8.15e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.87e-06	8.09e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	2.85e-06	8.04e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—ovarian cancer	2.81e-06	7.93e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—ovarian cancer	2.8e-06	7.9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—ovarian cancer	2.76e-06	7.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—ovarian cancer	2.74e-06	7.73e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—ovarian cancer	2.69e-06	7.58e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—ovarian cancer	2.68e-06	7.56e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	2.64e-06	7.44e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—ovarian cancer	2.57e-06	7.26e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—ovarian cancer	2.56e-06	7.23e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.54e-06	7.17e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.53e-06	7.12e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—ovarian cancer	2.48e-06	6.99e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—ovarian cancer	2.43e-06	6.85e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—ovarian cancer	2.38e-06	6.7e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.37e-06	6.7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—ovarian cancer	2.37e-06	6.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.33e-06	6.57e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.24e-06	6.33e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.21e-06	6.25e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.19e-06	6.18e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.06e-06	5.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—ovarian cancer	1.91e-06	5.4e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—ovarian cancer	1.83e-06	5.17e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—ovarian cancer	1.79e-06	5.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.75e-06	4.93e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—ovarian cancer	1.69e-06	4.76e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—ovarian cancer	1.43e-06	4.03e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.35e-06	3.81e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—ovarian cancer	1.1e-06	3.11e-05	CbGpPWpGaD
